A Study Assessing The Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Subcutaneous Bolus And Subcutaneous Infusion Of Cenderitide In Patients With Chronic Heart Failure With Volume Overload (HF)
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2012
At a glance
- Drugs Cenderitide (Primary)
- Indications Chronic heart failure
- Focus Biomarker; Pharmacokinetics
- 29 Mar 2012 Results were presented at the American College of Cardiology 61th Scientific Session.
- 27 Mar 2012 Results presented at the 61st Annual Scientific Session of the American College of Cardiology.
- 16 Nov 2011 Primary endpoint 'Pharmacokinetic-parameters' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History